ArticleNucleic acids research2012
5'-Triphosphate-RNA-independent activation of RIG-I via RNA aptamer with enhanced antiviral activity.
Article in Nucleic acids research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 72 citations in OpenAlex.
- Review
- Nucleic Acid Aptamers for Human Norovirus GII.4 and GII.17 Virus-Like Particles (VLPs) Exhibit Specific Binding and Inhibit VLPs from Entering Cells.International journal of nanomedicine · 2025Article
- RIG-I-mediated innate immune signaling in tumors reduces the therapeutic effect of oncolytic vesicular stomatitis virus.Thoracic cancer · 2023Article
- Therapeutic immunomodulation by rationally designed nucleic acids and nucleic acid nanoparticles.Frontiers in immunology · 2023Review
- Review
- Diagnosis and control of cryptosporidiosis in farm animals.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2022Review
- Aptamers for Viral Detection and Inhibition.ACS infectious diseases · 2022Review
- Marburg and Ebola Virus mRNA 3' Untranslated Regions Contain Negative Regulators of Translation That Are Modulated by ADAR1 Editing.Journal of virology · 2021Article
- Selection and applications of functional nucleic acids for infectious disease detection and prevention.Analytical and bioanalytical chemistry · 2021Review
- Systematic Evolution of Ligands by Exponential Enrichment Technologies and Aptamer-Based Applications: Recent Progress and Challenges in Precision Medicine of Infectious Diseases.Frontiers in bioengineering and biotechnology · 2021Review
- Review
- Enhanced target cell specificity and uptake of lipid nanoparticles using RNA aptamers and peptides.Beilstein journal of organic chemistry · 2021Article
- Recent advances in understanding oligonucleotide aptamers and their applications as therapeutic agents.3 Biotech · 2020Review
- A ribosomal RNA fragment with 2',3'-cyclic phosphate and GTP-binding activity acts as RIG-I ligand.Nucleic acids research · 2020Article
- RIG-I regulates myeloid differentiation by promoting TRIM25-mediated ISGylation.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Structural and biophysical properties of RIG-I bound to dsRNA with G-U wobble base pairs.RNA biology · 2020Article
- Review
- Recent Advances in Aptamer Discovery and Applications.Molecules (Basel, Switzerland) · 2019Review
- The Antiviral and Antitumor Effects of Defective Interfering Particles/Genomes and Their Mechanisms.Frontiers in microbiology · 2019Review
- Advancements in Nucleic Acid Based Therapeutics against Respiratory Viral Infections.Journal of clinical medicine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RIG-I is a cytosolic receptor for non-self RNA that mediates immune responses against viral infections through IFNα/β production. In an attempt to identify novel tools that modulate IFNα/β production, we used SELEX technology to screen RNA aptamers that specifically target RIG-I protein. Most of the selected RIG-I aptamers contained polyU motifs in the second half regions that played critical roles in the activation of RIG-I-mediated IFNβ production. Unlike other known ligands, RIG-I aptamer bound and activated RIG-I in a 5'-triphosphate-independent manner. The helicase and RD domain of RIG-I were used for aptamer binding, but intact RIG-I protein was required to exert aptamer-mediated signaling activation. Furthermore, replication of NDV, VSV and influenza virus in infected host cells was efficiently blocked by pre- or post-treatment with RIG-I aptamer. Based on these data, we propose that RIG-I aptamer has strong potential to be an antiviral agent that specifically boosts the RIG-I-dependent signaling cascade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.